In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China
The objective of this study was to better understand the in vitro activity of flomoxef against clinical extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. A total of 401 ESBL-producing isolates, including 196 Escherichia coli, 124 Klebsiella pneumoniae and 81 Proteus mirabilis, were collected consecutively from 21 hospitals in China in 2013. Minimum inhibitory concentrations (MICs) were determined by broth microdilution methods. Phenotypic identification of ESBL production was detected as recommended by the Clinical and Laboratory Standards Institute (CLSI). ESBL genes were detected by PCR and sequencing. Flomoxef, doripenem, meropenem, ertapenem, cefmetazole and piperacillin/tazobactam exhibited good activity against ESBL-producing isolates, with susceptibility rates >90%. Tigecycline showed good activity against E. coli and K. pneumoniae (100% and 97.6%, respectively). Cefotaxime and cefepime showed very low activities against ESBL-producing isolates, with susceptibility rates of 0-0.8% and 1.0-13.6%, respectively. blaCTX-M were the major ESBL genes, with occurrence in 99.5% of E. coli, 91.1% of K. pneumoniae and 97.5% of P. mirabilis. blaCTX-M-14 was the predominant ESBL gene, detected in 46.9% (188/401) of the isolates, followed by blaCTX-M-15 (21.4%), blaCTX-M-55 (17.2%), blaCTX-M-65 (12.7%) and blaCTX-M-3 (6.7%). Flomoxef exhibited excellent activity against the different CTX-M-type ESBL-producing isolates, with MIC50 and MIC90 values of 0.064-0.125μg/mL and 0.25-0.5μg/mL, respectively. Against the isolates solely producing CTX-M-14, -15, -55, -3 or -65, flomoxef showed susceptibility rates of 98.6%, 98.0%, 98.1%, 100.0% and 97.4%, respectively. In conclusion, flomoxef showed good activity against ESBL-producing Enterobacteriaceae and may be a choice to treat infections caused by these isolates in China..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
International journal of antimicrobial agents - 45(2015), 5, Seite 485-490 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Qiwen [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.ijantimicag.2014.11.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1958853623 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1958853623 | ||
| 003 | DE-627 | ||
| 005 | 20230714145744.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijantimicag.2014.11.012 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1958853623 | ||
| 035 | |a (DE-599)GBVOLC1958853623 | ||
| 035 | |a (PRQ)c972-51c1c70b7777900fd5980b4631b4268d6e5dbca21b03199dc59320533f00e1450 | ||
| 035 | |a (KEY)0202141220150000045000500485invitroactivityofflomoxefandcomparatorsagainstesch | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 100 | 1 | |a Yang, Qiwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The objective of this study was to better understand the in vitro activity of flomoxef against clinical extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. A total of 401 ESBL-producing isolates, including 196 Escherichia coli, 124 Klebsiella pneumoniae and 81 Proteus mirabilis, were collected consecutively from 21 hospitals in China in 2013. Minimum inhibitory concentrations (MICs) were determined by broth microdilution methods. Phenotypic identification of ESBL production was detected as recommended by the Clinical and Laboratory Standards Institute (CLSI). ESBL genes were detected by PCR and sequencing. Flomoxef, doripenem, meropenem, ertapenem, cefmetazole and piperacillin/tazobactam exhibited good activity against ESBL-producing isolates, with susceptibility rates >90%. Tigecycline showed good activity against E. coli and K. pneumoniae (100% and 97.6%, respectively). Cefotaxime and cefepime showed very low activities against ESBL-producing isolates, with susceptibility rates of 0-0.8% and 1.0-13.6%, respectively. blaCTX-M were the major ESBL genes, with occurrence in 99.5% of E. coli, 91.1% of K. pneumoniae and 97.5% of P. mirabilis. blaCTX-M-14 was the predominant ESBL gene, detected in 46.9% (188/401) of the isolates, followed by blaCTX-M-15 (21.4%), blaCTX-M-55 (17.2%), blaCTX-M-65 (12.7%) and blaCTX-M-3 (6.7%). Flomoxef exhibited excellent activity against the different CTX-M-type ESBL-producing isolates, with MIC50 and MIC90 values of 0.064-0.125μg/mL and 0.25-0.5μg/mL, respectively. Against the isolates solely producing CTX-M-14, -15, -55, -3 or -65, flomoxef showed susceptibility rates of 98.6%, 98.0%, 98.1%, 100.0% and 97.4%, respectively. In conclusion, flomoxef showed good activity against ESBL-producing Enterobacteriaceae and may be a choice to treat infections caused by these isolates in China. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. | ||
| 650 | 4 | |a Enterobacteriaceae Infections - microbiology | |
| 650 | 4 | |a Klebsiella pneumoniae - enzymology | |
| 650 | 4 | |a Proteus mirabilis - isolation & purification | |
| 650 | 4 | |a beta-Lactamases - secretion | |
| 650 | 4 | |a Klebsiella pneumoniae - drug effects | |
| 650 | 4 | |a Proteus mirabilis - drug effects | |
| 650 | 4 | |a beta-Lactamases - genetics | |
| 650 | 4 | |a Escherichia coli - enzymology | |
| 650 | 4 | |a Escherichia coli - isolation & purification | |
| 650 | 4 | |a Klebsiella pneumoniae - isolation & purification | |
| 650 | 4 | |a Escherichia coli - drug effects | |
| 650 | 4 | |a beta-Lactamases - analysis | |
| 650 | 4 | |a Cephalosporins - pharmacology | |
| 650 | 4 | |a Proteus mirabilis - enzymology | |
| 650 | 4 | |a Anti-Bacterial Agents - pharmacology | |
| 700 | 1 | |a Zhang, Hui |4 oth | |
| 700 | 1 | |a Cheng, Jingwei |4 oth | |
| 700 | 1 | |a Xu, Zhipeng |4 oth | |
| 700 | 1 | |a Xu, Yingchun |4 oth | |
| 700 | 1 | |a Cao, Bin |4 oth | |
| 700 | 1 | |a Kong, Haishen |4 oth | |
| 700 | 1 | |a Ni, Yuxing |4 oth | |
| 700 | 1 | |a Yu, Yunsong |4 oth | |
| 700 | 1 | |a Sun, Ziyong |4 oth | |
| 700 | 1 | |a Hu, Bijie |4 oth | |
| 700 | 1 | |a Huang, Wenxiang |4 oth | |
| 700 | 1 | |a Wang, Yong |4 oth | |
| 700 | 1 | |a Wu, Anhua |4 oth | |
| 700 | 1 | |a Feng, Xianju |4 oth | |
| 700 | 1 | |a Liao, Kang |4 oth | |
| 700 | 1 | |a Shen, Dingxia |4 oth | |
| 700 | 1 | |a Hu, Zhidong |4 oth | |
| 700 | 1 | |a Chu, Yunzhuo |4 oth | |
| 700 | 1 | |a Lu, Juan |4 oth | |
| 700 | 1 | |a Su, Jianrong |4 oth | |
| 700 | 1 | |a Gui, Bingdong |4 oth | |
| 700 | 1 | |a Duan, Qiong |4 oth | |
| 700 | 1 | |a Zhang, Shufang |4 oth | |
| 700 | 1 | |a Shao, Haifeng |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of antimicrobial agents |d Amsterdam : Elsevier, 1991 |g 45(2015), 5, Seite 485-490 |w (DE-627)170703088 |w (DE-600)1093977-5 |w (DE-576)435516655 |x 0924-8579 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2015 |g number:5 |g pages:485-490 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.ijantimicag.2014.11.012 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25600890 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2015 |e 5 |h 485-490 | ||